Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis

NCT06359041 is registered in ClinicalTrials.gov with Cabaletta Bio as lead sponsor.

NCT NCT06359041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06359041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESET-MG: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Generalized Myasthenia Gravis
Lead sponsor
Cabaletta Bio
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 17, 2024
Completion date
September 30, 2029
Enrollment
24 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis (gmg)